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ORIGINAL ARTICLE
Latent cytomegalovirus infection does not influence long-term disease
outcomes in inflammatory bowel disease, but is associated with later onset
of disease
Kimberley W. J. van der Sloota,b, Michiel D. Voskuila,c, Marijn C. Visschedijka, Eleonora A. M. Festena,c,
Hendrik M. van Dullemena, Rinse K. Weersmaa , Behrooz Z. Alizadehb, Coretta van Leer-Buterd† and
Gerard Dijkstraa†
aDepartment of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The
Netherlands; bDepartment of Epidemiology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands;
cDepartment of Genetics, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands; dDepartment of
Medical Microbiology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands
ABSTRACT
Objectives: Cytomegalovirus (CMV) infection is common in the general population. CMV infection
negatively affects disease course in transplant recipients and HIV patients. Whereas primary CMV infec-
tions may occur sporadically in seronegative patients, all seropositive patients with inflammatory
bowel syndrome (IBD) are at risk for CMV reactivation due to the inflammatory mucosal and use of
immunosuppressive medication. It is unclear whether latent CMV infection, and risk of reactivations,
influences long-term disease outcomes. In this study, we aim to explore whether CMV infection affects
disease outcomes in IBD patients.
Methods: We performed a cross-sectional cohort study with 1404 patients with IBD from a single cen-
ter. Clinical characteristics and disease outcomes were prospectively collected. We scrutinized CMV ser-
ology test results and performed additional CMV serology testing if serum was available.
Results: Out of 699 IBD patients with CMV serology, 303 (43.3%) were seropositive, comparable to the
general Dutch population. CMV seropositivity was associated with older age, longer IBD disease dur-
ation, non-Western origin, birth outside the Netherlands and a lower educational level (p-val-
ues .004). CMV seropositivity was not associated with more complicated long-term disease outcomes
of IBD (p-values> .05). Seropositive patients presented with symptoms and were diagnosed at an older
age compared to seronegative patients (p-values< .01).
Conclusions: CMV seropositivity does not influence disease outcomes of IBD patients and seems to
be associated with a delay in IBD onset. Guidelines regarding CMV screening in patients with IBD are
currently based on a low level of evidence. These data support the recommendation that routine CMV
serology measurement is not necessary in the clinical care of IBD.
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Inflammatory Bowel Disease (IBD), comprising ulcerative col-
itis (UC) and Crohn’s disease (CD), is a chronic relapsing
immune-mediated disease characterized by inflammation
and ulceration of the gut mucosa [1]. In UC, inflammation is
generally limited to the mucosal layer of the colon, whereas
in CD, inflammation may involve all layers of the gut and
may occur throughout the entire gastrointestinal tract [1].
The exact pathogenesis of IBD is complex, but it is likely that
a combination of genetic susceptibility and environmental
exposure leads to an exaggerated immune response to the
luminal microbial load of the gut [2–4].
Cytomegalovirus (CMV), a member of the herpes virus
family, is a virus that remains latently present in various tis-
sues and cell types following primary infections. Although
primary infections are usually asymptomatic or mild in
immunocompetent individuals, immune-deficient individuals,
including patients who are being treated with immunomo-
dulating (IM) drugs are prone to developing severe illness,
which may include CMV colitis, pneumonitis and even hemo-
phagcytic syndrome [5–7]. Moreover, patients who are not
completely immunocompetent remain at risk for developing
CMV reactivations, which may cause end-organ disease such
as colitis and pneumonitis [8]. Because CMV colitis clinically
resembles IBD relapse, the presence of this virus has recently
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been studied in biopsies taken from patients with symptoms
that could be caused by either disease [9]. So far research
has been inconclusive as to the significance of CMV in biop-
sies [10]. As CMV may be latently present in mucosal tissues
in all seropositive individuals, the simple finding of CMV
DNA does not prove causality [11]. Nonetheless, CMV reacti-
vations are likely in IBD patients who are being treated with
IM drugs, and cases of treatment-resistant IBD have been
reported showing viral replication in biopsies [12–14].
Seroprevalence of CMV varies between 40% and 100% of
adults depending on the population studied. A cross-sec-
tional seroprevalence study in the Netherlands showed that
small children have the highest chance of acquiring the
infection, with 22% of children already being seropositive at
the age of 9 and nearly 30% seropositivity at the age of 19.
Seroprevalence increases gradually to 45% between 40 and
49 years of age. Compared to many other regions of the
world, these percentages are relatively low [10,15,16].
Because all CMV seropositive patients with IBD IM treat-
ment are at risk of reactivation, we investigated if CMV sero-
prevalence is associated with less favorable outcome of IBD.
To answer this question, we determined the serostatus of all
patients in a well-characterized, large cohort of IBD patients




For this cross-sectional cohort study, we included IBD
patients enrolled in the 1000IBD cohort at the University
Medical Center Groningen (UMCG), a tertiary referral center
in the Netherlands [17]. Detailed demographics and disease
characteristics are prospectively collected by treating IBD
specialists during the course of ongoing patient care.
Long-term disease outcomes were defined as progression
to biological therapy or surgery. We used the Montreal classi-
fication to define disease characteristics and complications
such as fibrostenotic, penetrating or perianal disease in CD,
and the extent and severity of colitis in UC [18].
Next, we identified patients for whom a CMV serology test
was performed as part of clinical care (group A). When mul-
tiple CMV serology test results were available, the most recent
results were used for this study. Subsequently, patients for
whom no clinical CMV serology was available, were screened
for the availability of previously collected serum samples,
stored in our biobank by 80 C (PSI-UMCG [IRB no 08/279]).
If available, additional CMV serology tests were performed to
minimize potential selection bias (group B).
CMV measurements
All CMV serology tests were performed at the Department of
Medical Microbiology, UMCG. Immunoglobulin G antibodies
against CMV (anti-CMV IgG) were measured in plasma using
the Abbott ARCHITECT CMV IgG test [19]. Anti-CMV IgG 
5UA/mL was used as the cut-off value for CMV seropositivity.
As primary infection in adults is uncommon, the possible
effect of CMV results from reactivation of the latent virus
[20]. Since only patients with a latent infection are at risk for
reactivation, CMV seropositivity can be used as a proxy for
evaluation of the role of CMV in the disease course of
patients with IBD.
Statistical analysis
We first compared patient characteristics between patients
with a clinical CMV serology test (group A) and the remain-
ing cohort (Supplementary Table 1), and between all patients
with CMV serology tests (clinical and additional tests; groups
A and B) and the remaining cohort (Supplementary Table 2).
Next, patient characteristics were compared between sero-
positive and seronegative patients (Table 1). For categorical
variables, Chi-square tests were used and for continuous vari-
ables, depending on variable distribution, either one-way
ANOVA or Kruskal–Wallis H tests were used. We used mul-
tiple logistic regression modeling to estimate the effect
(odds ratio (OR) with 95% confidence interval (CI)) of CMV
infection on long-term disease outcomes and disease charac-
teristics as described by the Montreal classification. We
adjusted for potential confounders including age, sex, ethni-
city, country of birth, educational level, history of smoking,
disease duration and CMV test groups (A or B) to minimize
the possible influence of selection bias. Cases with missing
data on the mentioned potential confounders were excluded
from the analyses. Linear regression modeling was used to
estimate the effect of CMV infection on the age at disease
presentation. Linear regression models were adjusted for the
potential confounders including sex, ethnicity, country of
birth, educational level, history of smoking and CMV test
groups (A or B). Model assumptions were met. All P-values
were two-sided and p-values< .05 were considered signifi-
cant. SPSS Statistics version 23 (IBM Corp., Armonk, NY) was
used to perform statistical analyses.





Ageb Mean (SD) 49.3 (15.7) 41.4 (14.6)
Disease durationb Median (IQR) 14 (9–22) 12 (7–18)
Sex
Female n (%) 177 (58.4) 230 (58.1)
Type of IBD
Crohn’s disease n (%) 169 (55.8) 237 (59.8)
Ulcerative colitis n (%) 120 (39.6) 140 (35.4)
IBD unidentified n (%) 14 (4.6) 19 (4.8)
Originb
Western n (%) 256 (91.1) 363 (98.4)
Country of birthb
Netherlands n (%) 250 (86.8) 362 (97.1)
Smoking statusa
Ever n (%) 188 (62.3) 215 (54.4)
Educational levelb
Low n (%) 169 (62.6) 178 (51.1)
High n (%) 101 (37.4) 170 (48.9)
Age at symptom onsetb Median (IQR) 24 (17–40) 21 (15–29)
Age at diagnosis (exact)b Median (IQR) 25 (17–41) 24 (18–33)
CMV: cytomegalovirus; n: number; SD: standard deviation; IQR: interquar-
tile range.
aIndicates significant difference between groups, p-value < .05.
bIndicates significant difference between groups, p-value < .01.
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Ethical approval and consent to participate
The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori approval
by the institution’s human research committee. Ethical
approval for this study was granted in 2017 (no. 2017/407)
as well as for the PSI UMCG biobank in 2008 (no. 2008/279)
by the University Medical Center Groningen Ethics
Committee. Written informed consent was obtained for all
participants of the Biobank.
Results
In total, we obtained CMV serology test results for 699
(49.8%) patients, of which 413 tests (59.1%) were performed
as part of clinical care (group A) and an additional 286 tests
(40.9%) were performed specifically for this study (group B).
Patients for whom CMV serology was measured as part of
clinical care (group A) as well as the total group of tested
patients (groups A and B) were younger at the time of diag-
nosis (Montreal A) than patients without CMV test results.
Patients with UC for whom CMV serology was measured as
part of clinical care had more proximal disease extension
and more severe disease (Montreal E and S). The total group
(groups Aþ B) of patients with UC and CD with available
CMV serology more frequently progressed to the need for
biological therapy, while only group A had a higher surgery
rate compared to the remaining patients in our cohort (all p-
values < .05). There were no differences in surgery rate nor
Montreal classification between groups A and B
(Supplementary Tables 1 and 2).
CMV seroprevalence and development of IBD
Overall, the CMV seroprevalence in our cohort was 43.3%
and comparable between men and women. Seropositive
patients were more likely to be of non-Western origin, born
outside the Netherlands, to have a history of smoking and a
lower educational level compared to seronegative patients
(all p-values < .05). Seropositive patients were significantly
older (49.3 vs. 41.4 years), and had a longer disease duration
(14.0 vs. 12.0 years). There were no associations between
CMV infection and subtypes of IBD nor sex.
Remarkably, seropositive patients were 3 years older at
onset of symptoms (24.0 vs. 21.0 years), as well as 3 years
older at the time of IBD diagnosis (25.0 vs. 24.0 years; both
p-values <.001, Table 2). The differences remained significant
after correcting for confounding factors (age at onset of
symptoms [3.62 years, 95% CI 1.86 6.28, p-value <.001]; age
at diagnosis [3.33 years, 95% CI 1.45 5.61, p-value <.001]).
When UC and CD are analyzed separately, this association
remains significant only in UC age at onset of symptoms
[2.49 years, 95% CI 1.01 8.68, p-value ¼ .014] and age at
diagnosis [2.95 years, 1.74 8.77, p-value ¼ 0.004]), while a
trend is visible for CD. The time between onset of symptoms
and IBD diagnosis was not associated to CMV seropositivity
(p-value ¼ .84).
CMV Seropositivity and IBD disease course
CMV seropositivity was not a risk factor for long-term disease
outcomes including the need for biological therapy or sur-
gery, nor for a more complicated disease course including
fibrostenotic, penetrating or perianal disease in patients with
CD, or more proximal disease and severity of colitis in
patients with UC (all p-values > .10, Table 3).
Discussion
We report a CMV seroprevalence rate of 45% in patients
with IBD, which is comparable to the general Dutch popula-
tion [20]. We replicate known risk factors for CMV
Table 2. Univariate comparison of Montreal classification and disease outcomes based on CMV status.
Crohn’s disease (N: 406) Ulcerative colitis (N: 260)
CMV– CMV1 p value CMV– CMV1 p value
Age at diagnosis .13 Age at diagnosis <.01
< 17 yrs 48 (20.3) 24 (14.2) < 17 yrs 23 (16.4) 15 (12.5)
17–40 yrs 153 (64.6) 108 (63.9) 17–40 yrs 97 (69.3) 62 (51.7)
> 40 yrs 35 (14.8) 37 (21.9) > 40 yrs 20 (14.3) 43 (35.8)
Disease location .36 Disease extent .91
Ileal (L1) 81 (34.2) 59 (34.9) Proctitis (E1) 8 (5.7) 6 (5.0)
Colonic (L2) 46 (19.4) 33 (19.5) Distal (E2) 40 (28.6) 32 (26.7)
Ileocolonic (L3) 100 (42.2) 75 (44.4) Pancolitis (E3) 87 (62.1) 77 (64.2)
Upper-GI disease (L4) 24 (10.3) 25 (14.8) .18
Disease behavior .27 Disease severity .88
Inflammation only (B1) 118 (49.8) 82 (48.5) Asymptomatic (S1) 6 (4.3) 4 (3.3)
Stricturing (B2) 81 (34.2) 60 (35.5) Mild (S2) 29 (20.7) 26 (21.7)
Penetrating (B3) 33 (13.9) 27 (16.0) Moderate (S3) 56 (40.0) 40 (33.3)
Perianal (Bp) 76 (32.6) 55 (32.5) .99 Severe (S4) 43 (30.7) 35 (29.2)
Need for surgery 107 (45.1) 85 (50.3) .31 Need for colectomy 34 (24.3) 27 (22.5) .74
Medication usea .07 Medication usea .56
Steroids only 18 (7.7) 21 (12.9) Steroids only 33 (25.2) 28 (24.3)
Immunosuppressive drugs 55 (23.6) 47 (28.8) Immunosuppressive drugs 59 (45.0) 59 (51.3)
Biologicals 160 (68.7) 95 (58.3) Biologicals 39 (29.8) 28 (24.3)
MV-OR: multivariate-adjusted odds ratio; 95%CI: 95% confidence interval.
aAll medication types are analyzed as ever or never used in patients ongoing disease course. Biologicals include infliximab, adalimumab, golimumab and
certolizumab.
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seropositivity, including birth outside the Netherlands, non-
Western origin, and lower educational level [15,20,21]. A
similar study to this present study performed in China
reported a CMV seroprevalence rate of 78% in patients with
IBD, which may partially be explained by these risk factors
[22]. In addition, our results suggest that CMV seropositivity
is associated with a later onset of IBD, a three-year delay in
effect. To our knowledge, this effect has not previously
been described.
Regarding the impact of CMV seropositivity on IBD dis-
ease outcomes, contradictory findings have been reported
[9,23–26]. In our large, well-characterized IBD cohort, we did
not find any association between CMV seropositivity and
unfavorable IBD disease outcomes such as steroid-refractory
colitis, as expressed by the need for biological therapy or
subsequent colectomy. Our data do show, however, that IBD
gastroenterologists often still test for CMV antibodies in
patients with IBD, in particular in patients with a more severe
disease course and younger age, albeit against ECCO guide-
lines [27].
Since primary CMV infection in adults is uncommon and
unlikely to be asymptomatic in immune-deficient hosts, the
clinical impact of CMV most likely results from reactivation of
the latent virus [6]. If this reactivation were of significant clin-
ical impact, however, one would expect to find higher rates
of unfavorable outcome, such as treatment-refractory colitis
and subsequent surgery or use of biologicals in patients with
latent CMV infection, which was not the case in our study.
This suggests that CMV reactivations either have a self-limit-
ing inflammatory effect or that CMV is indeed an innocent
bystander in relapsing disease in most patients, that does
not affect long-term disease outcomes in the general IBD
population. Our findings support recommendations in the
ECCO guidelines and smaller cohort studies, that CMV ser-
ology testing is not recommended either in routine care or
prior to the start of immunosuppressive medication [13,27].
CMV colitis should still be considered in the diagnostic
workup prior to IBD diagnosis or in patients presenting with
deterioration of previously stable IBD unresponsive to inten-
sified therapy [27].
Unexpectedly, patients with a latent CMV infection had an
average of three-year delay in the onset of IBD compared to
IBD patients without a latent CMV infection. We are well
aware that this finding is merely an association and we do
not imply causation. A protective effect of CMV infections
against the development of IBD, however, seems unlikely
given the comparable CMV seroprevalence rates between
patients with IBD and the general population [20].
The strength of our study is our large prospective, well-
characterized cohort. This resulted in the replication of
known risk factors for CMV infection and allowed us to reli-
ably investigate the role of CMV on IBD disease outcomes.
Our study is limited by several factors. Since we use CMV
seropositivity as a proxy for reactivation, we cannot report
whether CMV infection caused colitis, let alone at which time
point. As a consequence, the possible temporary effects of
CMV reactivation, such as hospitalization and necessary anti-
viral therapies, remain unknown.
Prospective follow-up studies of seronegative and positive
patients might provide this insight. The presence of CMV
DNA in colonic biopsies is unknown for this cohort. However,
determining the exact time of CMV reactivation remains very
difficult, as anti-CMV IgM does not always develop, and the
presence of CMV DNA present in colonic biopsies may only
reflect latency without clinical significance [10]. Hence, data
on CMV DNA in biopsies would not have changed the overall
conclusion of this specific study.
In conclusion, we have shown that CMV seropositivity
does not influence disease outcomes of patients with IBD.
The onset of IBD is delayed in CMV seropositive patients.
These data support the recommendation given in the ECCO
guideline and confirm that routine measurement of CMV ser-
ology is not necessary in IBD.
Ethical approval
Ethical approval was obtained for the Biobank used in this
study (University Medical Center Groningen, Medical Ethics
Committee, registration no. 2017/407 and no. 08/279,
Table 3. Cytomegalovirus and disease outcomes using multivariate adjusted logistic regression models.
Crohn’s disease (N: 406) Ulcerative colitis (N:260)
MV-OR (95%CI)a Cases p-value MV-OR (95% CI)a Cases p-value
Disease location .27 Disease extent .19
Ileal (L1) 1.0 Ref, 113 Proctitis (E1) 1.0 Ref, 13
Colonic (L2) 1.09 (0.56–2.10) 67 Distal (E2) 0.99 (0.26–3.79) 62
Ileocolonic (L3) 1.35 (0.78–2.32) 152 Pancolitis (E3) 1.58 (0.44–5.71) 145
Upper-GI disease (L4) 1.50 (0.76–2.99) 45 .24
Disease behavior .88 Disease severity .47
Inflammatory only (B1) 1.0 Ref, 170 Mild (S1) 1.0 Ref, 48
Stricturing (B2) 0.89 (0.53–1.52) 117 Moderate (S2) 1.05 (0.48–2.28) 84
Penetrating (B3) 0.99 (0.50–1.96) 51 Severe (S3) 1.33 (0.59–3.01) 73
Perianal (Bp) 1.07 (0.66–1.75) 111 .78
Need for surgery 0.78 (0.47–1.29) 167 .33 Need for colectomy 0.95 (0.47–1.93) 48 .88
Need for biologicalsb 0.68 (0.42–1.10) 218 .12 Need for biologicalsb 1.07 (0.53–2.16) 51 .89
MV-OR: multivariate-adjusted odds ratio; 95%CI: 95% confidence interval; anti-TNFa: anti-tumor necrosis factor alpha.
aAll MV-adjusted ORs were corrected for sex, age (in years), ethnicity (Caucasian/non-Caucasian), disease duration (in years), cigarette smoking (ever/never), edu-
cational level (low/high), country of birth (the Netherlands/other country), type of CMV test (as part of clinical care/additionally performed for this study).
bBiologicals include: infliximab, adalimumab, golimumab and certolizumab (ever/never).
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respectively). Written informed consent is obtained from all
participants of the Biobank.
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